This book offers a conceptual explanation of the interrelationships that exist between the stages in the progression of initiated epithelial cells in culture compared with the diverse tissue of organs and the progression of tumors from different organ sites. The fate of the modification of adducts is discussed at the molecular level. The role that modifications in hot spots in oncogenes and supressor genes play at the molecular level and how these molecular modifications can lead to an explanation of molecular control in the formation of tumor phenotypes is also examined. Researchers in cell biology and toxicology, applied pharmacology, carcinogenesis, teratogenesis, mutagenesis, and molecular toxicology will find the book useful, interesting reading.

This book offers a conceptual explanation of the interrelationships that exist between the stages in the progression of initiated epithelial cells in culture compared with the diverse tissue of organs and the progression of tumors from different organ sites. The fate of the modification of adducts is discussed at the molecular level. The role that modifications in hot spots in oncogenes and supressor genes play at the molecular level and how these molecular modifications can lead to an explanation of molecular control in the formation of tumor phenotypes is also examined. Researchers in cell biology and toxicology, applied pharmacology, carcinogenesis, teratogenesis, mutagenesis, and molecular toxicology will find the book useful, interesting reading.

Translational Advances in Gynecologic Cancers straddles the bench and bed divide by highlighting important and interesting research that is translatable to the clinic. The contents of this book cover the entire spectrum, from promising laboratory based research, to clinical trial efforts. Further, new therapeutic indications based upon randomized phase III trials are also included. Clinicians will learn about lab-based science that is about to enter the clinic, along with the rationale behind translational endpoints in trials. Researchers will be able to identify and understand the clinical needs of patients with these types of tumors to improve their research focus.